Translational issues in precision medicine in neuropathic pain
Neuropathic pain remains poorly treated, with most new drugs falling through the translational gap. The traditional model of bench-to-bedside research has relied on identifying new mechanisms/targets in animal models and then developing clinical applications. Several have advocated bridging the tran...
Main Authors: | Anthony H. Dickenson, Ryan Patel |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Canadian Journal of Pain |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/24740527.2020.1720502 |
Similar Items
-
Neuropathic pain in children: Steps towards improved recognition and management
by: Suellen M Walker
Published: (2020-12-01) -
Statins and Neuropathic Pain: A Narrative Review
by: Joseph V. Pergolizzi, et al.
Published: (2020-02-01) -
Quantitative sensory profiles of upper extremity chemotherapy induced peripheral neuropathy: Are there differences in sensory profiles for neuropathic versus nociceptive pain?
by: Elizabeth Andersen Hammond, et al.
Published: (2019-01-01) -
Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
by: Russell J, et al.
Published: (2010-01-01) -
Opstacles in neuropathic pain treatment in the developing country: Neuropathic pain treatment
by: Jovičić Jelena, et al.
Published: (2018-01-01)